A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

Inclusion Criteria: * Participants must have received a PD-1 PDLI therapy within 9 weeks of starting dosing on this study \[for example, nivolumab, pembrolizumab, atezolizumab\] * Participants must be willing to have tumor biopsies * Participants must have adequate organ function * Participants must have Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 * Participants must be able to swallow tablets * Participants with stable, previously treated brain metastases may participate if neurologic symptoms have resolved and participants have been off steroids for at least 14 days Exclusion Criteria: * Participants must not have moderate or severe cardiovascular disease * Participants must not have active autoimmune disease (for example Crohn's disease, Hashimotos disease, etc) * Participants must not have an active infection requiring treatment